

Mild and Metal-Free Diastereoselective Synthesis of N-tert-Butanesulfinylamines by Using Tetrakis(dimethylamino)ethylene

Cédric Spitz, Anna Lin, Thierry Terme, Patrice Vanelle

► **To cite this version:**

Cédric Spitz, Anna Lin, Thierry Terme, Patrice Vanelle. Mild and Metal-Free Diastereoselective Synthesis of N-tert-Butanesulfinylamines by Using Tetrakis(dimethylamino)ethylene. SYNTHESIS, Georg Thieme Verlag, 2014, 10.1055/s-0034-1378636 . hal-01425582

HAL Id: hal-01425582

<https://hal-amu.archives-ouvertes.fr/hal-01425582>

Submitted on 3 Jan 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Mild and Metal-Free Diastereoselective Synthesis of *N*-*tert*-Butanesulfinylamines by Using Tetrakis(dimethylamino)ethylene

Cédric Spitz, Anna Lin, Thierry Terme, Patrice Vanelle*

Aix-Marseille Université, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 Boulevard Jean Moulin – CS 30064 – 13385 Marseille Cedex 05, France

Fax +33(4)91794677; E-mail: patrice.vanelle@univ-amu.fr

Received: 19.05.2014; Accepted after revision: 18.07.2014

Abstract: A mild and metal-free diastereoselective synthesis of *N*-*tert*-butanesulfinylamines was developed by using a strategy based on tetrakis(dimethylamino)ethylene. Good yields and diastereoselectivities were achieved by addition of *o*-nitrobenzyl chloride or 4-[4-(chloromethyl)phenyl]-1,2-dimethyl-5-nitro-1*H*-imidazole to readily available *N*-*tert*-butanesulfinimines.

Key words: sulfinimines, diastereoselectivity, amines, metal-free, chiral auxiliary


The asymmetric synthesis of amines has received considerable attention in recent years because nitrogen-containing molecules are ubiquitous components of biologically active compounds.¹ Adding a nucleophile to enantiomerically pure *N*-*tert*-butanesulfinimines is one of the most commonly used methods for the asymmetric synthesis of amines.² In particular, adding organometallic reagents to *N*-sulfinimines usually leads to the synthesis of amine products in good yields and diastereoselectivities. Furthermore, the *tert*-butanesulfinyl chiral auxiliary can be removed easily under acidic conditions, giving the corresponding chiral primary amines. However, the disadvantage of using organometallic reagents such as Grignard or organolithium reagents is their poor functional group tolerance. Recently, Ellman and co-workers reported the MgCl₂-enhanced addition of benzyl zinc reagents to *N*-*tert*-butanesulfinimines, obtaining good yields, diastereoselectivities and better functional group tolerance.³ However, to our knowledge, the addition of organometallic reagents bearing a nitro group to *N*-*tert*-butanesulfinimines has never been described, probably due to the difficulty of generating organometallic nitro compounds.⁴

Tetrakis(dimethylamino)ethylene (TDAE) is an organic reducing agent that reacts with halogenated derivatives to generate a carbanion under mild conditions.⁵ Since 2003, our research has focused on developing original synthetic methods using TDAE methodology in medicinal chemistry.⁶ Recently, we reported the application of our TDAE methodology to the diastereoselective addition of *p*-nitrobenzyl chloride to a variety of enantiopure (*R*)-*N*-*tert*-butanesulfinimines, producing chiral amines in good yields and diastereoselectivities.⁷

As part of our research program on new bioactive compounds,⁸ we report herein the diastereoselective synthesis of chiral amines through the addition of either *o*-nitrobenzyl chloride (**1**) or 4-[4-(chloromethyl)phenyl]-1,2-dimethyl-5-nitro-1*H*-imidazole (**4**) to enantiopure (*R*)-*N*-*tert*-butanesulfinimines using TDAE.

First, to compare the influence of an *ortho* substituent with that of a *para* substituent on the benzyl chloride system, the commercially available **1** was used in the reaction with sulfinimines **2a–g** in the presence of TDAE at –20 °C for one hour, followed by 20 hours at room temperature. Under these conditions, a variety of *N*-*tert*-butanesulfinylamines were obtained in good yields (52–66%) and with good diastereoselectivities (from 83:17 to 89:11). The results are summarised in Table 1. Sulfinimines with *para*-, *meta*-, and *ortho*-substitution were all well tolerated and, encouragingly, the substituents did not affect diastereoselectivity (entries 1–6). Interestingly, the use of heteroar-

Table 1 Diastereoselective Addition of **1** to (Hetero)Aromatic Sulfinimines **2a–g** by Using the TDAE Strategy^a



Entry	Imine 2	Ar(Het)	Yield (%) ^b of 3	dr ^c
1	2a	4-O ₂ NC ₆ H ₄	66	89:11
2	2b	3-O ₂ NC ₆ H ₄	60	88:12
3	2c	2-O ₂ NC ₆ H ₄	59	87:13
4	2d	4-BrC ₆ H ₄	52	89:11
5	2e	4-NCC ₆ H ₄	62	89:11
6	2f	3-NCC ₆ H ₄	65	83:17
7	2g	2-pyridyl	59	87:13

^a Reaction conditions: chloride **1** (1 equiv), imine **2** (1.2 equiv), TDAE (1 equiv), anhydrous DMF, –20 °C, 1 h, then r.t., 20 h.

^b Combined yield of diastereoisomers after purification by chromatography.

^c Determined after separation of the two diastereoisomers by chromatography.

SYNTHESIS 2014, 46, 3229–3232

Advanced online publication: 27.08.2014

DOI: 10.1055/s-0034-1378636; Art ID: ss-2014-z0307-op

© Georg Thieme Verlag Stuttgart · New York

matic imine **2g** allowed the formation of the corresponding amine **3g** in good yield and diastereoselectivity (entry 7).

To extend the scope of the reaction to other benzyl chloride derivatives containing a nitro group and because the 5-nitroimidazole moiety is well known to exhibit a wide spectrum of anti-infectious activity,⁹ we then performed the reaction between **4** and various enantiopure (hetero)aromatic *N*-sulfinimines **2a**, **2d–e**, and **2g–k**. In the presence of TDAE, the corresponding amines were obtained in moderate to good yields (41–78%) and good diastereoselectivities (from 82:18 to 89:11), as shown in Table 2. Reactions with electron-poor aromatic imines produced good yields and good diastereoselectivities (entries 1–3 and 5–6). The diastereoselectivity obtained with the unsubstituted imine **2j** was still good but, as expected, the yield was slightly diminished (entry 7). The electron-rich imine **2k**, with a methoxy substituent, also gave good diastereoselectivity, and 44% yield was obtained by using imine **2k** (1 equiv), chloride **4** (3 equiv), and TDAE (3 equiv; entry 8). Again, it is interesting to note that the use of heteroaromatic imine **2g** allowed the formation of the corresponding amine **5g** in good yield and diastereoselectivity (entry 4). It should be noted that a bis-heteroaromatic compound such as the latter would be very difficult to synthesise by using organometallic chemistry.

The absolute configuration of the major diastereoisomer was assigned as *R,R* by analogy with our previous communication.⁶


In summary, a mild and metal-free diastereoselective synthesis of *N-tert*-butanesulfinylamines was developed by using a TDAE strategy. The tolerance of nitro groups proved that this method is a good alternative to the use of organometallic reagents to prepare enantiopure amines containing nitro substituents.

All chemicals and reagents were purchased from commercial suppliers. Melting points were determined with a Büchi melting point B-540 apparatus and are uncorrected. Both ¹H and ¹³C NMR spectra were determined with Bruker AC 200, Bruker 300 Avance III nanobay and Bruker 400 Avance III nanobay spectrometers. The ¹H and the ¹³C chemical shifts are reported from CDCl₃ peaks: ¹H (δ = 7.26 ppm) and ¹³C (δ = 77.16 ppm). Multiplicities are represented by the following notations: singlet (s), doublet (d), triplet (t), quartet (q), and complex multiplet or overlapping multiplets (m). HRMS analyses were recorded with a SYNAPT G2HDMS (Waters) apparatus at the spectropole of the Aix-Marseille University. The following adsorbents were used for column chromatography: silica gel 60 (Merck, particle size 0.063–0.200 mm, 70–230 mesh ASTM). TLC was performed on 5 × 10 cm aluminium plates coated with silica gel 60 F254 (Merck) in an appropriate solvent.

General Procedure

To a stirred solution of *N*-sulfinimine **2** (0.24 mmol) in anhydrous DMF (1 mL) at –20 °C was added TDAE (0.2 mmol) followed by dropwise addition of a solution of **1** or **4** in anhydrous DMF (1 mL). The solution was vigorously stirred at –20 °C for 1 h and then maintained at r.t. for 20 h. H₂O (5 mL) was added and the aqueous solution was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layer was washed with H₂O (20 mL) and dried over MgSO₄. Evaporation of the solvent furnished the crude product, which was purified

Table 2 Diastereoselective Addition of **4** to (Hetero)Aromatic Sulfinimines **2** by Using the TDAE Strategy^a



Entry	Imine 2	Ar(Het)	Yield (%) ^b of 5	dr ^c
1	2a	4-O ₂ NC ₆ H ₄	57	82:18
2	2d	4-BrC ₆ H ₄	54	89:11
3	2e	4-NCC ₆ H ₄	78	88:12
4	2g	2-pyridyl	49	85:15
5	2h	3-BrC ₆ H ₄	66	85:15
6	2i	2-BrC ₆ H ₄	54	83:17
7	2j	Ph	41	83:17
8	2k	3-MeOC ₆ H ₄	44 ^d	83:17

^a Reaction conditions: chloride **4** (1 equiv), imine **2** (1.2 equiv) and TDAE (1 equiv) in anhydrous DMF, –20 °C, 1 h, then r.t., 20 h.

^b Combined yield of diastereoisomers after purification by chromatography.

^c Determined after separation of the two diastereoisomers by chromatography.

^d Imine **2k** (1 equiv), chloride **4** (3 equiv), TDAE (3 equiv) were used.

fied by silica gel chromatography to give the two diastereoisomers of amine products **3** or **5**.

(*R*)-*N*-[1-(4-Nitrophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (**3a**)

Eluent: EtOAc–PE (6:4 → 1:0). Major diastereoisomer (*R,R*).

Yield: 52 mg (66%); yellow solid; mp 152–154 °C.

¹H NMR (200 MHz, CDCl₃): δ = 8.20 (d, *J* = 8.8 Hz, 2 H), 7.96 (dd, *J* = 8.0, 1.4 Hz, 1 H), 7.55–7.38 (m, 4 H), 7.29–7.24 (m, 1 H), 4.86–4.75 (m, 1 H), 3.89 (d, *J* = 7.4 Hz, 1 H), 3.53 (dd, *J* = 13.6, 8.6 Hz, 1 H), 3.34 (dd, *J* = 13.6, 6.2 Hz, 1 H), 1.05 (s, 9 H).

¹³C NMR (50 MHz, CDCl₃): δ = 149.6, 149.2, 147.6, 133.2, 132.3, 128.4, 127.9, 125.2, 124.1, 60.7, 56.5, 40.8, 22.3 (1 carbon signal missing due to overlap).

HRMS (ESI): *m/z* [M + H]⁺ calcd for [C₁₈H₂₂N₃O₅S]⁺: 392.1275; found: 392.1277.

(*R*)-*N*-[1-(3-Nitrophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (**3b**)

Eluent: EtOAc–PE (6:4 → 1:0). Major diastereoisomer (*R,R*).

Yield: 47 mg (60%); yellow solid; mp 153–154 °C.

¹H NMR (200 MHz, CDCl₃): δ = 8.22 (s, 1 H), 8.14 (d, *J* = 8.2 Hz, 1 H), 7.96 (dd, *J* = 8.0, 1.2 Hz, 1 H), 7.71 (d, *J* = 7.6 Hz, 1 H), 7.57–7.29 (m, 4 H), 4.86–4.75 (m, 1 H), 3.99 (d, *J* = 7.4 Hz, 1 H), 3.55 (dd, *J* = 13.6, 8.8 Hz, 1 H), 3.36 (dd, *J* = 13.6, 6.2 Hz, 1 H), 1.05 (s, 9 H).

^{13}C NMR (50 MHz, CDCl_3): δ = 149.6, 148.4, 144.1, 133.4, 133.3, 133.2, 132.4, 129.9, 128.3, 125.2, 123.2, 121.8, 60.7, 56.5, 40.7, 22.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{18}\text{H}_{22}\text{N}_3\text{O}_5\text{S}]^+$: 392.1275; found: 392.1274.

(*R*)-*N*-[1-(2-Nitrophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (3c)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 46 mg (59%); yellow solid; mp 69–71 °C.

^1H NMR (200 MHz, CDCl_3): δ = 8.00–7.90 (m, 2 H), 7.74–7.59 (m, 4 H), 7.50–7.42 (m, 2 H), 5.34–5.22 (m, 1 H), 4.68 (d, J = 9.8 Hz, 1 H), 3.55 (dd, J = 13.6, 10.0 Hz, 1 H), 3.36 (dd, J = 13.8, 5.0 Hz, 1 H), 0.92 (s, 9 H).

^{13}C NMR (50 MHz, CDCl_3): δ = 150.0, 148.1, 137.9, 134.0, 133.4, 133.0, 132.6, 129.9, 128.8, 128.1, 125.2, 124.7, 59.0, 56.6, 39.0, 22.2.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{18}\text{H}_{22}\text{N}_3\text{O}_5\text{S}]^+$: 392.1275; found: 392.1276.

(*R*)-*N*-[1-(4-Bromophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (3d)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 44 mg (52%); yellow solid; mp 153–155 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.92 (dd, J = 8.2, 1.4 Hz, 1 H), 7.49–7.37 (m, 4 H), 7.24–7.17 (m, 3 H), 4.70–4.60 (m, 1 H), 3.68 (d, J = 6.0 Hz, 1 H), 3.55 (dd, J = 13.6, 8.2 Hz, 1 H), 3.29 (dd, J = 13.6, 6.6 Hz, 1 H), 1.07 (s, 9 H).

^{13}C NMR (50 MHz, CDCl_3): δ = 140.7, 133.2, 132.9, 132.7, 132.0, 131.8, 128.7, 128.0, 125.0, 122.1, 60.4, 56.2, 40.6, 22.4.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{18}\text{H}_{22}\text{BrN}_2\text{O}_3\text{S}]^+$: 425.0529; found: 425.0529.

(*R*)-*N*-[1-(4-Cyanophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (3e)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 46 mg (62%); yellow solid; mp 175–177 °C.

^1H NMR (300 MHz, CDCl_3): δ = 7.94 (dd, J = 8.1, 1.2 Hz, 1 H), 7.62 (d, J = 8.4 Hz, 2 H), 7.54–7.38 (m, 4 H), 7.25 (d, J = 7.5 Hz, 1 H), 4.77–4.69 (m, 1 H), 3.93 (d, J = 7.5 Hz, 1 H), 3.49 (dd, J = 13.5, 8.7 Hz, 1 H), 3.32 (dd, J = 13.5, 6.3 Hz, 1 H), 1.04 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 149.6, 147.2, 133.2, 133.1, 132.6, 132.4, 128.3, 127.8, 125.1, 118.5, 112.0, 60.9, 56.4, 40.7, 22.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{19}\text{H}_{22}\text{N}_3\text{O}_3\text{S}]^+$: 372.1376; found: 372.1378.

(*R*)-*N*-[1-(3-cyanophenyl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (3f)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 48 mg (65%); yellow solid; mp 97–99 °C.

^1H NMR (400 MHz, CDCl_3): δ = 7.95 (d, J = 8.2 Hz, 1 H), 7.61–7.58 (m, 3 H), 7.52–7.41 (m, 4 H), 4.75–4.70 (m, 1 H), 3.84 (d, J = 6.8 Hz, 1 H), 3.53 (dd, J = 13.6, 8.4 Hz, 1 H), 3.32 (dd, J = 13.6, 6.0 Hz, 1 H), 1.06 (s, 9 H).

^{13}C NMR (100 MHz, CDCl_3): δ = 149.7, 143.4, 133.2, 133.1, 132.3, 131.8, 131.6, 130.5, 129.7, 128.3, 125.2, 118.5, 112.9, 60.5, 56.4, 40.7, 22.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{19}\text{H}_{22}\text{N}_3\text{O}_3\text{S}]^+$: 372.1376; found: 372.1377.

(*R*)-*N*-[1-(Pyridin-2-yl)-2-(2-nitrophenyl)ethyl]-2-methylpropane-2-sulfinamide (3g)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 41 mg (59%); yellow oil.

^1H NMR (200 MHz, CDCl_3): δ = 8.58 (d, J = 4.6 Hz, 1 H), 7.98 (d, J = 8.0 Hz, 1 H), 7.73–7.66 (m, 1 H), 7.48–7.28 (m, 5 H), 5.18 (d, J = 8.8 Hz, 1 H), 4.86–4.75 (m, 1 H), 3.46 (dd, J = 13.4, 5.4 Hz, 1 H), 3.30 (dd, J = 13.4, 9.2 Hz, 1 H), 1.09 (s, 9 H).

^{13}C NMR (50 MHz, CDCl_3): δ = 160.4, 149.6, 149.1, 137.4, 134.2, 133.4, 132.8, 128.0, 125.0, 123.0, 122.3, 61.7, 56.2, 41.9, 22.7.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{17}\text{H}_{22}\text{N}_3\text{O}_3\text{S}]^+$: 348.1376; found: 348.1374.

(*R*)-*N*-{2-[4-(1,2-Dimethyl-5-nitro-1*H*-imidazol-4-yl)phenyl]-1-(4-nitrophenyl)ethyl}-2-methylpropane-2-sulfinamide (5a)

Eluent: EtOAc-PE (6:4 \rightarrow 1:0). Major diastereoisomer (*R,R*).

Yield: 55 mg (57%); yellow solid; mp 111–113 °C.

^1H NMR (200 MHz, CDCl_3): δ = 8.15 (d, J = 8.8 Hz, 2 H), 7.62 (d, J = 8.0 Hz, 2 H), 7.42 (d, J = 8.0 Hz, 2 H), 7.06 (d, J = 8.0 Hz, 2 H), 4.78–4.69 (m, 1 H), 3.90 (s, 3 H), 3.72 (d, J = 5.2 Hz, 1 H), 3.34 (dd, J = 13.6, 6.8 Hz, 1 H), 3.07 (dd, J = 13.6, 7.6 Hz, 1 H), 2.51 (s, 3 H), 1.16 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 149.0, 148.4, 147.5, 143.1, 137.7, 134.7, 130.6, 129.7, 129.2, 128.3, 123.8, 60.5, 56.5, 43.4, 34.2, 22.5, 14.2.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{28}\text{N}_5\text{O}_5\text{S}]^+$: 486.1806; found: 486.1805.

(*R*)-*N*-{2-[4-(1,2-Dimethyl-5-nitro-1*H*-imidazol-4-yl)phenyl]-1-(4-bromophenyl)ethyl}-2-methylpropane-2-sulfinamide (5d)

Eluent: EtOAc-PE (6:4) \rightarrow EtOAc-MeOH (40:1). Major diastereoisomer (*R,R*).

Yield: 56 mg (54%); yellow solid; mp 87–89 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.60 (d, J = 8.2 Hz, 2 H), 7.40 (d, J = 8.2 Hz, 2 H), 7.12 (d, J = 8.4 Hz, 2 H), 7.06 (d, J = 8.4 Hz, 2 H), 4.62–4.52 (m, 1 H), 3.88 (s, 3 H), 3.71 (d, J = 4.6 Hz, 1 H), 3.29 (dd, J = 13.4, 6.6 Hz, 1 H), 3.00 (dd, J = 13.4, 7.6 Hz, 1 H), 2.50 (s, 3 H), 1.14 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 148.3, 143.3, 140.6, 138.5, 131.7, 130.2, 129.5, 129.3, 129.0, 121.8, 60.3, 56.2, 43.3, 34.2, 22.5, 14.2; 1 carbon signal missing due to overlap.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{28}\text{BrN}_4\text{O}_3\text{S}]^+$: 519.1060; found: 519.1060.

(*R*)-*N*-{2-[4-(1,2-Dimethyl-5-nitro-1*H*-imidazol-4-yl)phenyl]-1-(4-cyanophenyl)ethyl}-2-methylpropane-2-sulfinamide (5e)

Eluent: EtOAc-PE (6:4) \rightarrow EtOAc-MeOH (20:1). Major diastereoisomer (*R,R*).

Yield: 73 mg (78%); yellow solid; mp 112–114 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.61–7.54 (m, 4 H), 7.34 (d, J = 8.2 Hz, 2 H), 7.04 (d, J = 8.0 Hz, 2 H), 4.70–4.60 (m, 1 H), 3.87 (s, 3 H), 3.77 (d, J = 5.4 Hz, 1 H), 3.29 (dd, J = 13.4, 7.0 Hz, 1 H), 3.02 (dd, J = 13.4, 7.2 Hz, 1 H), 2.49 (s, 3 H), 1.12 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 148.3, 146.9, 143.1, 137.8, 132.4, 130.6, 129.6, 129.2, 128.1, 118.6, 111.8, 60.6, 56.4, 43.3, 34.2, 22.5, 14.2; 1 carbon signal missing due to overlap.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{24}\text{H}_{28}\text{N}_5\text{O}_3\text{S}]^+$: 466.1907; found: 466.1906.

(*R*)-*N*-{2-[4-(1,2-dimethyl-5-nitro-1*H*-imidazol-4-yl)phenyl]-1-(pyridin-2-yl)ethyl}-2-methylpropane-2-sulfinamide (5g)

Eluent: EtOAc-PE (6:4) \rightarrow EtOAc-MeOH (9:1). Major diastereoisomer (*R,R*).

Yield: 43 mg (49%); yellow oil.

^1H NMR (300 MHz, CDCl_3): δ = 8.56 (d, J = 4.5 Hz, 1 H), 7.62–7.55 (m, 3 H), 7.20–7.10 (m, 4 H), 4.88 (d, J = 7.8 Hz, 1 H), 4.70–4.63 (m, 1 H), 3.87 (s, 3 H), 3.16 (d, J = 7.2 Hz, 2 H), 2.49 (s, 3 H), 1.14 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 160.4, 149.0, 148.4, 143.6, 139.2, 137.2, 134.9, 130.2, 129.5, 129.4, 122.8, 122.6, 62.4, 56.3, 44.3, 34.3, 22.8, 14.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{22}\text{H}_{28}\text{N}_5\text{O}_3\text{S}]^+$: 442.1907; found: 442.1908.

(R)-N-{2-[4-(1,2-dimethyl-5-nitro-1H-imidazol-4-yl)phenyl]-1-(3-bromophenyl)ethyl}-2-methyl propane-2-sulfinamide (5h)
Eluent: EtOAc–PE (6:4) \rightarrow EtOAc–MeOH (40:1). Major diastereoisomer (*R,R*).

Yield: 69 mg (66%); yellow solid; mp 107–109 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.60 (d, J = 8.2 Hz, 2 H), 7.47 (s, 1 H), 7.40–7.35 (m, 1 H), 7.16–7.09 (m, 4 H), 4.58–4.48 (m, 1 H), 4.14 (d, J = 6.4 Hz, 1 H), 3.87 (s, 3 H), 3.25 (dd, J = 13.6, 7.4 Hz, 1 H), 3.03 (dd, J = 13.6, 7.2 Hz, 1 H), 2.49 (s, 3 H), 1.10 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 148.3, 144.0, 143.3, 138.4, 134.8, 131.1, 130.3, 130.2, 130.1, 129.5, 129.3, 126.3, 122.7, 60.4, 56.2, 43.4, 34.2, 22.5, 14.2.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{28}\text{BrN}_4\text{O}_3\text{S}]^+$: 519.1060; found: 519.1063.

(R)-N-{2-[4-(1,2-Dimethyl-5-nitro-1H-imidazol-4-yl)phenyl]-1-(2-bromophenyl)ethyl}-2-methyl propane-2-sulfinamide (5i)
Eluent: EtOAc–PE (6:4) \rightarrow EtOAc–MeOH (40:1). Major diastereoisomer (*R,R*).

Yield: 56 mg (54%); yellow solid; mp 113–115 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.65 (d, J = 8.2 Hz, 2 H), 7.54 (d, J = 7.8 Hz, 1 H), 7.42–7.12 (m, 5 H), 5.07–4.97 (m, 1 H), 3.96 (d, J = 6.6 Hz, 1 H), 3.90 (s, 3 H), 3.24 (dd, J = 13.6, 5.4 Hz, 1 H), 3.04 (dd, J = 13.6, 8.2 Hz, 1 H), 2.51 (s, 3 H), 1.05 (s, 9 H).

^{13}C NMR (50 MHz, CDCl_3): δ = 148.3, 143.4, 140.7, 138.8, 133.2, 130.3, 129.6, 129.4, 129.2, 128.8, 127.8, 123.2, 60.5, 56.6, 42.6, 34.2, 22.4, 14.2; 1 carbon signal missing due to overlap.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{28}\text{N}_4\text{O}_3\text{SBr}]^+$: 519.1060; found: 519.1063.

(R)-N-(2-(4-(1,2-dimethyl-5-nitro-1H-imidazol-4-yl)phenyl)-1-(phenyl)ethyl)-2-methyl propane-2-sulfinamide (5j)
Eluent: EtOAc–PE (6:4) \rightarrow EtOAc–MeOH (9:1). Major diastereoisomer (*R,R*).

Yield: 36 mg (41%); yellow solid; mp 82–84 °C.

^1H NMR (200 MHz, CDCl_3): δ = 7.60 (d, J = 8.2 Hz, 2 H), 7.28–7.24 (m, 5 H), 7.07 (d, J = 8.2 Hz, 2 H), 4.67–4.58 (m, 1 H), 3.89 (s, 3 H), 3.59 (d, J = 3.8 Hz, 1 H), 3.34 (dd, J = 13.4, 6.6 Hz, 1 H), 3.06 (dd, J = 13.4, 7.6 Hz, 1 H), 2.51 (s, 3 H), 1.16 (s, 9 H).

^{13}C NMR (75 MHz, CDCl_3): δ = 148.3, 143.5, 141.5, 139.0, 130.0, 129.4, 129.3, 128.6, 127.9, 127.8, 127.3, 60.7, 56.1, 43.5, 34.1, 22.6, 14.2.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{23}\text{H}_{29}\text{N}_4\text{O}_3\text{S}]^+$: 441.1955; found: 441.1957.

(R)-N-{2-[4-(1,2-Dimethyl-5-nitro-1H-imidazol-4-yl)phenyl]-1-(3-methoxyphenyl)ethyl}-2-methyl Propane-2-sulfinamide (5k)
Eluent: EtOAc–PE (6:4) \rightarrow EtOAc–MeOH (40:1). Major diastereoisomer (*R,R*).

Yield: 39 mg (44%); yellow solid; mp 92–94 °C.

^1H NMR (400 MHz, CDCl_3): δ = 7.60 (d, J = 8.4 Hz, 2 H), 7.19 (dd, J = 8.0, 7.6 Hz, 1 H), 7.08 (d, J = 8.0 Hz, 2 H), 6.85–6.77 (m, 3 H), 4.61–4.57 (m, 1 H), 3.88 (s, 3 H), 3.74 (s, 3 H), 3.58 (d, J = 4.0 Hz, 1 H), 3.30 (dd, J = 13.4, 6.6 Hz, 1 H), 3.05 (dd, J = 13.4, 7.8 Hz, 1 H), 2.49 (s, 3 H), 1.15 (s, 9 H).

^{13}C NMR (100 MHz, CDCl_3): δ = 159.7, 148.3, 143.5, 143.2, 139.0, 130.1, 129.6, 129.39, 129.37, 119.5, 113.4, 112.9, 60.7, 56.1, 55.2, 43.4, 34.2, 22.6, 14.2; 1 carbon signal missing due to overlap.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $[\text{C}_{24}\text{H}_{31}\text{N}_4\text{O}_4\text{S}]^+$: 471.2061; found: 471.2060.

Acknowledgment

This work was supported by the CNRS and the Aix-Marseille University. The authors thank the Spectropole team for HRMS analysis. We express our thanks to V. Remusat for recording ^1H and ^{13}C NMR spectra.

References

- (1) Hili, R.; Yudin, A. K. *Nat. Chem. Biol.* **2006**, *2*, 284.
- (2) Robak, M. T.; Herbage, M. A.; Ellman, J. A. *Chem. Rev.* **2010**, *110*, 3600.
- (3) Buesking, A. W.; Baguley, T. D.; Ellman, J. A. *Org. Lett.* **2011**, *13*, 964.
- (4) Sapountzis, I.; Dube, H.; Lewis, R.; Gommermann, N.; Knochel, P. *J. Org. Chem.* **2005**, *70*, 2445.
- (5) (a) Takechi, N.; Ait-Mohand, S.; Médebielle, M.; Dolbier, W. R. Jr. *Tetrahedron Lett.* **2002**, *43*, 4317. (b) Pooput, C.; Médebielle, M.; Dolbier, W. R. Jr. *Org. Lett.* **2004**, *6*, 301. (c) Pooput, C.; Médebielle, M.; Dolbier, W. R. Jr. *J. Org. Chem.* **2006**, *71*, 3564.
- (6) (a) Montana, M.; Terme, T.; Vanelle, P. *Tetrahedron Lett.* **2005**, *46*, 8373. (b) Amiri-Attou, O.; Terme, T.; Vanelle, P. *Molecules* **2005**, *10*, 545. (c) Montana, M.; Terme, T.; Vanelle, P. *Tetrahedron Lett.* **2006**, *47*, 6573. (d) Juspín, T.; Terme, T.; Vanelle, P. *Synlett* **2009**, 1485. (e) Nadji-Boukrouche, A. R.; Khoumeri, O.; Terme, T.; Liacha, M.; Vanelle, P. *ARKIVOC* **2010**, (x), 358. (f) Montana, M.; Terme, T.; Vanelle, P. *Lett. Org. Chem.* **2010**, *7*, 453. (g) Juspín, T.; Giuglio-Tonolo, G.; Terme, T.; Vanelle, P. *Synthesis* **2010**, 844.
- (7) Spitz, C.; Khoumeri, O.; Terme, T.; Vanelle, P. *Synlett* **2013**, *24*, 1725.
- (8) (a) Crozet, M. P.; Archaimbault, G.; Vanelle, P.; Nouguié, R. *Tetrahedron Lett.* **1985**, *26*, 5133. (b) Curti, C.; Laget, M.; Ortiz Carle, A.; Gellis, A.; Vanelle, P. *Eur. J. Med. Chem.* **2007**, *42*, 880. (c) Cohen, A.; Crozet, M. D.; Rathelot, P.; Vanelle, P. *Green Chem.* **2009**, *11*, 1736. (d) Verhaeghe, P.; Azas, N.; Hutter, S.; Castera-Ducros, C.; Laget, M.; Dumètre, A.; Gasquet, M.; Reboul, J.-P.; Rault, S.; Rathelot, P.; Vanelle, P. *Bioorg. Med. Chem.* **2009**, *17*, 4313.
- (9) (a) Jorgensen, M. A.; Manos, J.; Mendz, G. L.; Hazell, S. L. *J. Antimicrob. Chemother.* **1998**, *41*, 67. (b) Upcroft, J. A.; Campbell, R. W.; Benakli, K.; Upcroft, P.; Vanelle, P. *Antimicrob. Agents Chemother.* **1999**, *43*, 73. (c) Citron, D. M.; Tyrrell, K. L.; Warren, Y. A.; Fernandez, H.; Merriam, C. V.; Goldstein, E. J. C. *Anaerobe* **2005**, *11*, 315. (d) Leitsch, D.; Kolarich, D.; Wilson, I. B. H.; Altmann, F.; Duchêne, M. *PLoS Biol.* **2007**, *5*, e211. (e) Crozet, M. D.; Botta, C.; Gasquet, M.; Curti, C.; Rémusat, V.; Hutter, S.; Chapelle, O.; Azas, N.; De Méo, M.; Vanelle, P. *Eur. J. Med. Chem.* **2009**, *44*, 653. (f) Kim, P.; Kang, S.; Boshoff, H. I.; Jiricek, J.; Collins, M.; Singh, R.; Manjunatha, U. H.; Niyomrattanakit, P.; Zhang, L.; Goodwin, M.; Dick, T.; Keller, T. H.; Dowd, C. S.; Barry, C. E. III *J. Med. Chem.* **2009**, *52*, 1329. (g) Dunn, L. A.; Burgess, A. G.; Krauer, K. G.; Eckmann, L.; Vanelle, P.; Crozet, M. D.; Gillin, F. D.; Upcroft, P.; Upcroft, J. A. *Int. J. Antimicrob. Agents* **2010**, *36*, 37.